GlobeNewswire · Press release
| Range | 6M |
|---|---|
| First date | — |
| Last date | — |
| Open | — |
| High | — |
| Low | — |
| Close | — |
| Volume | — |
| Plotted bars | 0 |
Event records
Event records load after the price chart.
Healthcare · Biotechnology
The Quantellect read. TLX rose 1.19% in the Nov 18 session to $8.96. The borrow fee is 15.05%. Three active firms cover the stock as of Nov 19, 2026; three active firms with targets average $21.33 over 12 months. Descriptive summary of the data on this page, not a recommendation.
—
RSI (14) 47.0 (overbought above 70, oversold below 30)
—
FINRA settlement Oct 30, 2026
Price $8.96 · As of Nov 18, 2026, 3:59 PM ET
| Range | 6M |
|---|---|
| First date | — |
| Last date | — |
| Open | — |
| High | — |
| Low | — |
| Close | — |
| Volume | — |
| Plotted bars | 0 |
Event records load after the price chart.
| Range | 6M |
|---|---|
| First close | — |
| Last close | — |
| High | — |
| Low | — |
| Volume | — |
TLX · NASDAQ · USD
Split-adjusted · volume in shares
— · Notable price movement not available
— · Options flow not available
— · Industry comparison not available
Buy
Based on 3 active firms as of Nov 19, 2026 (365-day activity window)
As of Nov 19, 2026 across 3 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →In the last 60 days: 0 insider sales and 0 purchases. No congressional trades in 90 days.
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops
Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.